ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences - Alimera Sciences ( NASDAQ:ALIM ) , ANI Pharmaceuticals ( NASDAQ:ANIP )
Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a pro forma basis Adds two durable commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI's foothold in strategic therapeutic area of ...
| Ticker |
Sentiment |
Impact |
|
PWP
|
Neutral
|
2 %
|
|
ALIM
|
Neutral
|
6 %
|
|
ANIP
|
Somewhat Bullish
|
6 %
|
